Calcium channel blockers diltiazem
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that diltiazem, a calcium channel blocker, can improve diabetic conditions, treat supraventricular tachycardia, alleviate noncardiac chest pain, inhibit neutrophil calcium release, block cardiac calcium channels, reverse multidrug resistance, and reduce ischemic myocardial damage.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
The Role of Diltiazem as a Calcium Channel Blocker
Introduction to Calcium Channel Blockers
Calcium channel blockers (CCBs) are a class of medications that inhibit the entry of calcium ions into cardiac and smooth muscle cells through L-type calcium channels. This inhibition leads to various therapeutic effects, including vasodilation, reduced heart rate, and decreased myocardial contractility. Among the CCBs, diltiazem is widely used for its efficacy in treating cardiovascular conditions such as hypertension, angina pectoris, and certain arrhythmias.
Diltiazem in Metabolic Control of Diabetes
Research has shown that diltiazem can have beneficial effects on metabolic control in diabetic conditions. In a study involving streptozotocin-induced diabetic rats, diltiazem treatment resulted in improved body weight, reduced blood glucose levels, and lower glycated hemoglobin levels compared to untreated diabetic rats. This suggests that diltiazem may help mitigate some of the metabolic disturbances associated with diabetes.
Emergency Treatment of Supraventricular Tachycardia
Diltiazem has also been evaluated for its efficacy in the emergency treatment of supraventricular tachycardia (SVT). A prospective randomized controlled trial compared the use of slow infusion diltiazem with intravenous adenosine. The study found that diltiazem had a higher conversion rate for SVT (98%) compared to adenosine (86.5%), with minimal hypotensive episodes, making it a viable alternative in settings where adenosine is not available.
Diltiazem for Nutcracker Esophagus
In patients with nutcracker esophagus, characterized by high-amplitude esophageal contractions causing chest pain and dysphagia, diltiazem has shown promise. A double-blind, cross-over trial demonstrated that diltiazem significantly reduced esophageal contraction pressure and chest pain scores compared to placebo, indicating its potential to alleviate symptoms in this condition.
Mechanisms of Action in Neutrophils
Diltiazem also affects intracellular calcium dynamics in neutrophils. It inhibits the movement of calcium from the cytosol to intracellular stores, which is crucial for various cellular functions, including phagocytosis and signaling. This inhibition can impact neutrophil function and has implications for immune response modulation.
Structural Insights into Diltiazem Binding
X-ray crystallographic studies have provided detailed insights into how diltiazem binds to voltage-gated calcium channels. Diltiazem targets the central cavity of the channel, blocking ion conduction. This binding site overlaps with that of other calcium antagonists like verapamil, and its interaction is modulated by other drugs such as amlodipine, which can alter diltiazem's binding affinity.
Comparative Potency and Binding Specificity
Comparative studies have shown that certain derivatives of calcium channel blockers can be more potent than diltiazem. These derivatives interact with the same binding site on the calcium channel, suggesting that modifications to the diltiazem structure could enhance its efficacy. Additionally, diltiazem has been found to preferentially block inactivated cardiac calcium channels, which may explain its effectiveness in treating arrhythmias.
Reversal of Multidrug Resistance
Diltiazem has also been studied for its ability to reverse multidrug resistance in cancer cells. It binds specifically to membrane vesicles of multidrug-resistant cells and inhibits drug binding to P-glycoprotein, thereby increasing the accumulation of chemotherapeutic agents in resistant cells.
Cardioprotective Effects in Ischemia-Reperfusion Injury
In the context of ischemia-reperfusion injury, diltiazem has shown protective effects. It reduces the harmful consequences of reperfusion, such as creatine phosphokinase leakage, fibrillation, and contracture, by mitigating mitochondrial calcium overload.
Pharmacokinetics and Clinical Use
Diltiazem is well-absorbed after oral administration but undergoes significant first-pass metabolism, resulting in moderate bioavailability. Its onset of action is relatively fast, and it has a short elimination half-life, necessitating multiple daily doses or the use of extended-release formulations for chronic conditions.
Conclusion
Diltiazem is a versatile calcium channel blocker with applications ranging from metabolic control in diabetes to emergency treatment of SVT and symptom relief in nutcracker esophagus. Its mechanisms of action, structural binding insights, and potential to reverse multidrug resistance highlight its therapeutic significance. Further research and development of diltiazem derivatives may enhance its clinical efficacy and broaden its therapeutic applications.
Sources and full results
Most relevant research papers on this topic
